Evidence map›Paper›PMID 35664298›Full record

ArticleFrontiers in genetics2022

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma.

Aneta Polewko-Klim, Sibo Zhu, Weicheng Wu, Yijing Xie, Ning Cai, Kexun Zhang, Zhen Zhu, Tao Qing, Ziyu Yuan, Kelin Xu and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Aneta Polewko-KlimInstitute of Computer Science, University in Bialystok, Białystok, Poland.
Sibo ZhuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Weicheng WuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Yijing XieDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Ning CaiDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Kexun ZhangDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Zhen ZhuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Tao QingFudan-Taizhou Institute of Health Sciences, Taizhou, China.
Ziyu YuanFudan-Taizhou Institute of Health Sciences, Taizhou, China.
Kelin XuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Tiejun ZhangDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Ming LuFudan-Taizhou Institute of Health Sciences, Taizhou, China.
Weimin YeFudan-Taizhou Institute of Health Sciences, Taizhou, China.
Xingdong ChenFudan-Taizhou Institute of Health Sciences, Taizhou, China.
Chen SuoDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Witold R RudnickiInstitute of Computer Science, University in Bialystok, Białystok, Poland.
Fudan University · CNState Key Laboratory of Genetic EngineeringInstitute of Computer Science · PLKarolinska Institutet · SEQilu Hospital of Shandong University · CNUniversity of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard therapy administered to patients with advanced esophageal cancer remains uniform, despite its two main histological subtypes, namely esophageal squamous cell carcinoma (SCC) and esophageal adenocarcinoma (AC), are being increasingly considered to be different. The identification of potential drug target genes between SCC and AC is crucial for more effective treatment of these diseases, given the high toxicity of chemotherapy and resistance to administered medications. Herein we attempted to identify and rank differentially expressed genes (DEGs) in SCC

Indexed as

drug target genesensemble learning (EL)esophageal cancer (ESCA)Feature Selection (FS)random forest (RF)

Identifiers

PMID35664298
PMCPMC9161154
OpenAlexW4280503279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.